Obesity and diabetes as comorbidities for COVID-19: Underlying mechanisms and the role of viral–bacterial interactions

Authors:
Open Access
Publisher website
Google Scholar
Abstract
Obesity and diabetes are established comorbidities for COVID-19. Adipose tissue demonstrates high expression of ACE2 which SARS- CoV-2 exploits to enter host cells. This makes adipose tissue a reservoir for SARS-CoV-2 viruses and thus increases the integral viral load. Acute viral infection results in ACE2 downregulation. This relative deficiency can lead to disturbances in other systems controlled by ACE2, including the renin-angiotensin system. This will be further increased in the case of pre-conditions with already compromised functioning of these systems, such as in patients with obesity and diabetes. Here, we propose that interactions of virally-induced ACE2 deficiency with obesity and/or diabetes leads to a synergistic further impairment of endothelial and gut barrier function. The appearance of bacteria and/or their products in the lungs of obese and diabetic patients promotes interactions between viral and bacterial pathogens, resulting in a more severe lung injury in COVID-19.
Funding Information
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK55758)
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01-DK099110)
  • National Institute of Diabetes and Digestive and Kidney Diseases (RC2-DK118620)
  • National Institute of Diabetes and Digestive and Kidney Diseases (P01-DK088761)
  • National Institute on Aging (P01-AG051459)

This publication has 132 references indexed in Scilit: